Evidence map›Paper›PMID 37900838›Full record

ArticleCase reports in oncology

Advanced Female Primary Urethral Carcinoma with Nodal Extension Managed with Exclusive Use of Chemoradiotherapy: Report of a Case and Review of the Relevant Current Literature.

Moncef Al Barajraji, Serge Holz, Ilan Moussa, Michel Naudin, Mathieu Coscarella, Maria-Dolores Martin Martinez, Stéphanie Dingenen, Adèle Baize, Stephen Taylor

Open access · goldAbstract readCase Reports
In one paragraph

Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Moncef Al BarajrajiDepartment of Urology, Ambroise Pare Hospital, Mons, Belgium.
Serge HolzDepartment of Urology, Ambroise Pare Hospital, Mons, Belgium.
Ilan MoussaDepartment of Urology, Ambroise Pare Hospital, Mons, Belgium.
Michel NaudinDepartment of Urology, Ambroise Pare Hospital, Mons, Belgium.
Mathieu CoscarellaDepartment of Urology, Ambroise Pare Hospital, Mons, Belgium.
Maria-Dolores Martin MartinezDepartment of Anatomical Pathology, Ambroise Pare Hospital, Mons, Belgium.
Stéphanie DingenenDepartment of Oncology, Ambroise Pare Hospital, Mons, Belgium.
Adèle BaizeDepartment of Oncology, Ambroise Pare Hospital, Mons, Belgium.
Stephen TaylorDepartment of Radiology, Ambroise Pare Hospital, Mons, Belgium.
CHU Ambroise Paré · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary urethral carcinoma (PUC) is a rare disease with frequent nodal metastasis at the time of diagnosis. Few risk factors have been established and overall prognosis remains poor. As of now, no clear therapeutic guidelines are established and management of advanced PUC often involves surgery which can have negative functional and psychological outcomes for the patient. Few authors have already reported the use of chemoradiotherapy alone to avoid surgery with some good short-term results. We report the case of a 48-year-old woman with advanced high-grade urothelial carcinoma of distal urethra associated to bilateral inguinal nodal metastasis. She was similarly and successfully treated using chemoradiotherapy exclusively without significant adverse effects. This experience reinforces benefits of a surgery-sparing management, when possible, as recommended in current guidelines.

Indexed as

Advanced primary urethral carcinomaChemoradiotherapyFemaleOncologyPrimary urethral carcinoma

Identifiers

PMID37900838
PMCPMC10601767
OpenAlexW4387542756

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.